Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Biofrontera (BFRIW) Convertible Debt (2024 - 2025)

Biofrontera has reported Convertible Debt over the past 2 years, most recently at $4.6 million for Q4 2025.

  • Quarterly results put Convertible Debt at $4.6 million for Q4 2025, up 11.98% from a year ago — trailing twelve months through Dec 2025 was $4.6 million (up 11.98% YoY), and the annual figure for FY2025 was $4.6 million, up 11.98%.
  • Convertible Debt for Q4 2025 was $4.6 million at Biofrontera, up from $4.5 million in the prior quarter.
  • Over the last five years, Convertible Debt for BFRIW hit a ceiling of $4.6 million in Q4 2025 and a floor of $4.1 million in Q4 2024.